Mukosat

General characteristics. Structure:

Active ingredient: 250 mg of chondroitin of sulfate in 1 capsule.

Pharmacological properties:

Pharmacodynamics. Mukosat — the main component of the proteoglycans making a cartilaginous matrix together with collagenic fibers. Has hondroprotektorny properties; suppresses activity of the enzymes causing degradation of a joint cartilage; stimulates development with chondrocytes of proteoglycans; strengthens metabolic processes in a cartilage and a subchondral bone; exerts impact on phosphorus-calcium exchange in cartilaginous tissue, stimulates its regeneration, participates in creation of the main substance of bone and cartilaginous tissue.

Chondroitin sulfate has antiinflammatory and analgeziruyushchy properties, promotes decrease in emission in synovial fluid of mediators of an inflammation and painful factors through sinoviotsita and macrophages of a synovial membrane, suppresses secretion of B4 leukotriene and E2 prostaglandin. Drug promotes recovery of a joint bag of cartilaginous surfaces of joints, interferes with compression of connecting fabric, carries out a role of lubricant of joint surfaces; normalizes products of joint liquid, improves mobility of joints. Improves quality of life.

Pharmacokinetics. After intake the maximum concentration of drug in plasma (Cmax) is reached in 3 — 4 h, in synovial fluid — in 4 — 5 h. Bioavailability makes about 13%. Drug is removed from an organism generally by kidneys during 24 h.

Indications to use:

Drug is used at degenerative diseases of joints and a backbone, primary arthrosis, intervertebral osteochondrosis, an osteoarthrosis, osteoporosis, fractures of extremities, a periodontopathy.

Route of administration and doses:

Drug is accepted inside, washing down with a small amount of water. The adult appoint 750 mg (3 capsules on 0,25 g) 2 times a day within the first 3 weeks, further — on 500 mg (2 capsules on 0,25 g) 2 times a day.

Duration of a course of treatment — 4 — 5 weeks; at various forms of a periodontopathy — not less than 3 months. A repeated course — in 6 months.

Features of use:

The clinical effect at administration of drug occurs slowly, however remains is long within several months after the termination of a course of treatment. For the prevention of aggravations repeated courses of treatment are shown.

Side effects:

At administration of drug allergic reactions are possible.

Interaction with other medicines:

At the combined use with non-steroidal anti-inflammatory drugs (sodium diclofenac, etc.) allows to lower a dose of the last.

Contraindications:

Hypersensitivity to chondroitin to sulfate, tendency to bleeding, thrombophlebitises, pregnancy, feeding by a breast (for the period of treatment feeding by a breast should be stopped).

Overdose:

The overdose phenomena at administration of drug are not described.

Issue conditions:

According to the recipe

Packaging:

Capsules of 250 mg in a blister strip packaging No. 10х2, No. 10х3.